TL;DR
Turn quiet afternoons into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
An analysis of prospectively logged menstrual cycles found that users of a combined GLP-1/GIP receptor agonist had a larger reduction in cycle length and lower cycle variability than GLP-1-only users and never-users. The observational findings, presented at the American Society for Reproductive Medicine meeting, do not show that the medication caused the changes.
An analysis of 70,134 prospectively logged menstrual cycles linked use of a combined GLP-1/GIP receptor agonist with a larger reduction in cycle length and slightly lower cycle variability than GLP-1-only use or no use. The findings, presented by Shruthi Mahalingaiah and colleagues at the American Society for Reproductive Medicine annual meeting, show an association—not proof that the drug caused more regular periods.
Among participants using a combined GLP-1/GIP drug in the past year, cycle length fell by an average of 2.5 days. The corresponding reductions were 0.4 days for GLP-1 medication users and 0.8 days for never-users. Mean individual cycle variability was 6.93 days for combined-drug users, compared with 7.45 days among GLP-1-only users and 7.46 days among never-users.
The analysis drew on the Apple Women’s Health Study, a U.S. digital cohort. Researchers included 1,945 participants younger than 50 who were not pregnant or lactating, were not using hormones, had cycle lengths between 10 and 90 days, and had logged at least three cycles. The sample comprised 123 combined GLP-1/GIP users, 258 GLP-1 users and 1,564 never-users. Participants reported medication use and health information; researchers used menstrual records shared from HealthKit, not sensor-based data.
In a subgroup with polyendocrine metabolic ovarian syndrome, or PMOS, formerly called PCOS, mean cycle variability was 5.80 days among combined-drug users, 7.34 days among GLP-1 users and 9.45 days among never-users. The study did not establish why the groups differed, and the results do not show that any medication should be prescribed to regulate menstruation.
Potential Relevance for Ovulatory Health
Irregular periods can matter beyond fertility planning. As reproductive endocrinologist Rachel Weinerman told MedPage Today, cycle irregularity may also signal underlying health issues. The results may prompt further study of whether incretin medicines are associated with changes in ovulation or menstrual patterns, particularly for people with PMOS.
The findings are not evidence that these drugs are established treatments for irregular cycles. Medication users in the analysis differed from never-users in some respects: they were older on average and more likely to report PMOS, infertility, type 2 diabetes and hypertension. Those differences, alongside the observational design, make it difficult to separate a medication association from other factors, including weight change and underlying health.
Products Worth Considering
Fitbit Versa 2 Health and Fitness Smartwatch with Heart Rate, Alexa, Music, Sleep and Swim Tracking
Fitbit Inspire 3 Health and Fitness Tracker Bundle
Oura Ring 5 Smart Ring, Silver, Size 8
As an affiliate, we earn on qualifying purchases.
How Researchers Tracked Menstrual Cycles
Incretin medicines include GLP-1 receptor agonists and drugs that act on both GLP-1 and GIP receptors. The source report identifies tirzepatide (Zepbound) as the only GLP-1/GIP drug approved by the FDA. The analysis grouped participants according to reported medication use in the previous year; it did not provide agent-specific results.
Earlier retrospective studies had suggested a connection between these medicines and menstrual regularity, according to Mahalingaiah’s team. The researchers said this analysis was designed to examine cycle length and variability using prospectively logged records. Mahalingaiah said the study aimed to show the potential impact with more detail. The research was presented at a meeting, and the report does not describe it as a randomized trial.
“This more pronounced reduction among PMOS individuals might suggest a separate pathway that might focus on ovulatory health in addition to those metabolic parameters that support ovulation, but further research is necessary.”
— Shruthi Mahalingaiah, MD, MS, of the Harvard T.H. Chan School of Public Health
Causation and Drug-Specific Effects
The analysis cannot establish that the medication produced the changes in cycle length or variability. It did not randomly assign treatment, and the groups differed in health characteristics. The reported results also do not identify whether effects varied by specific drug, dose, duration of use or amount of weight change.
The source report says future manuscripts will break down the data by individual agents. It does not provide a treatment recommendation, a measure of clinical benefit for an individual patient, or evidence that the observed differences persist over time. The number and characteristics of participants may also limit how broadly the results apply.
Further Analysis of Individual Drugs
Mahalingaiah said future reports will examine the data by particular agents. Further research would be needed to test whether incretin medicines cause changes in menstrual patterns, clarify the role of weight loss and other metabolic changes, and assess whether the association differs for people with PMOS.
For now, the meeting findings are an observational signal rather than a basis for changing treatment. The source report does not announce a clinical trial or provide a date for the next analysis.
Key Questions
Did the study prove that the combined drug makes periods more regular?
No. It found an association in an observational cohort; it did not establish that the medication caused the changes.
What cycle changes did researchers report?
Average cycle length fell by 2.5 days among combined GLP-1/GIP users, versus 0.4 days among GLP-1 users and 0.8 days among never-users. Cycle variability was also lower in the combined-drug group, though the reported measures do not establish a treatment effect.
What did the PMOS subgroup show?
Mean individual cycle variability was 5.80 days among combined-drug users, 7.34 days among GLP-1 users and 9.45 days among never-users. Researchers said further work is needed to explain the difference.
Does this mean incretin drugs should be used to regulate periods?
The study does not support that conclusion. It was not a randomized treatment trial and does not provide prescribing guidance. Medication decisions should be discussed with a qualified health professional.
Source: medpagetoday.com
